125 related articles for article (PubMed ID: 20955108)
1. Evaluation of models for predicting drug-drug interactions due to induction.
Fahmi OA; Ripp SL
Expert Opin Drug Metab Toxicol; 2010 Nov; 6(11):1399-416. PubMed ID: 20955108
[TBL] [Abstract][Full Text] [Related]
2. Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models.
Marathe PH; Rodrigues AD
Methods Mol Biol; 2010; 596():385-403. PubMed ID: 19949933
[TBL] [Abstract][Full Text] [Related]
3. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
[TBL] [Abstract][Full Text] [Related]
4. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
5. Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances.
Obach RS
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):81-9. PubMed ID: 19152216
[TBL] [Abstract][Full Text] [Related]
6. [Tobacco smoking and drug interactions].
Molden E; Spigset O
Tidsskr Nor Laegeforen; 2009 Mar; 129(7):632-3. PubMed ID: 19337332
[TBL] [Abstract][Full Text] [Related]
7. Induction of drug metabolism: species differences and toxicological relevance.
Graham MJ; Lake BG
Toxicology; 2008 Dec; 254(3):184-91. PubMed ID: 18824059
[TBL] [Abstract][Full Text] [Related]
8. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
[TBL] [Abstract][Full Text] [Related]
9. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
10. [Quantitative prediction of in vivo drug-drug interactions based on in vitro inhibition or/and induction data for CYP3A4].
Zhang QH; Li Y
Yao Xue Xue Bao; 2010 Aug; 45(8):952-9. PubMed ID: 21351581
[TBL] [Abstract][Full Text] [Related]
11. Managing the Risk of CYP3A Induction in Drug Development: A Strategic Approach.
Jones BC; Rollison H; Johansson S; Kanebratt KP; Lambert C; Vishwanathan K; Andersson TB
Drug Metab Dispos; 2017 Jan; 45(1):35-41. PubMed ID: 27777246
[TBL] [Abstract][Full Text] [Related]
12. Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry--do they comply with FDA recommendations?
Hewitt NJ; de Kanter R; LeCluyse E
Chem Biol Interact; 2007 May; 168(1):51-65. PubMed ID: 17239835
[TBL] [Abstract][Full Text] [Related]
13. Updates on cytochrome P450-mediated cardiovascular drug interactions.
Cheng JW; Frishman WH; Aronow WS
Am J Ther; 2009; 16(2):155-63. PubMed ID: 19114873
[TBL] [Abstract][Full Text] [Related]
14. Use of clearance concepts and modeling techniques in the prediction of metabolic drug-drug interactions.
Ito K; Sugiyama Y
Trends Pharmacol Sci; 2010 Aug; 31(8):351-5. PubMed ID: 20542578
[TBL] [Abstract][Full Text] [Related]
15. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
Foti RS; Wahlstrom JL
IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
[TBL] [Abstract][Full Text] [Related]
16. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
Tang C; Lin JH; Lu AY
Drug Metab Dispos; 2005 May; 33(5):603-13. PubMed ID: 15673596
[TBL] [Abstract][Full Text] [Related]
17. Network analysis of adverse drug interactions.
Takarabe M; Okuda S; Itoh M; Tokimatsu T; Goto S; Kanehisa M
Genome Inform; 2008; 20():252-9. PubMed ID: 19425139
[TBL] [Abstract][Full Text] [Related]
18. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
[TBL] [Abstract][Full Text] [Related]
19. Challenges for drug studies in children: CYP3A phenotyping as example.
de Wildt SN; Ito S; Koren G
Drug Discov Today; 2009 Jan; 14(1-2):6-15. PubMed ID: 18721895
[TBL] [Abstract][Full Text] [Related]
20. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
